Article metrics

  • citations in SCindeks: 0
  • citations in CrossRef:0
  • citations in Google Scholar:[=>]
  • visits in previous 30 days:1
  • full-text downloads in 30 days:1
article: 8 from 14  
Back back to result list
Vojnosanitetski pregled
2008, vol. 65, iss. 12, pp. 901-905
article language: Serbian
document type: Original Paper
published on: 08/01/2009
doi: 10.2298/VSP0812901M
Cerebrospinal fluid amyloid beta and tau protein: Biomarkers for Alzheimer's disease
aClinical Center of Serbia, Clinic for Neurology, Belgrade
bClinical Center of Serbia, Center for Medical Biochemistry, Belgrade
cClinical Center of Serbia, Clinic for Orthopaedic Surgery and Traumatology, Belgrade



Background/Aim. Introduction of acetylcholine esterase inhibitors as a symptomatic treatment of Alzheimer's disease (AD) has additionally highlighted the importance of diagnostic markers in cerebrospinal fluid (CSF) for early AD diagnosis: low level of 42 amino acid form of amyloid-β peptide (Aβ42), and levels of tau protein (T-tau) and phosphorylated tau protein (P-tau). The aim of this study was to diagnostic potential of CSF biomarkers T-tau, P-tau and Aβ42 as biochemical markers for AD. Methods. Lumbar puncture was performed in 63 patients with AD and 26 control subjects who passed orthopedic surgery. The Innotest, ELISA sandwich test (Innogenetics - Belgium) was used for measuring the levels of T-tau, P-tau and Aβ42. Results. The patients and the control group did not differ in age, education and sex. Mean levels of CSF T-tau and P-tau were significantly higher in the patients with AD (p < 0.001) compared to the control group, in contrast to significantely lower CSF Aβ42 in AD group (p < 0.001). A significant progressive decrease of Aβ42, as well as significant progressive increase of T-tau and P-tau was found among AD subgroups (according to MMSE staging) and controls. Conclusion. The obtained results suggest that these biomarkers may be supportive in the diagnosis of AD, especially in the early course of the disease and could be used in the routine clinical practice considering the approaching target therapeutics.


Alzheimer disease; cerebrospinal fluid; biologicalmarkers; amyloid beta-protein; tau proteins


American Psychiatric Association (1994) Diagnostic and Statistical Manual for Mental Disorders. Washington, DC, 4th ed
Andreasen, N., Vanmechelen, E., van de Voorde, A., Davidsson, P., Hesse, C., Tarvonen, S., Räihä, I., Sourander, L., Winblad, B., Blennow, K. (1998) Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community based follow up study. J Neurol Neurosurg Psychiatry, 64(3): 298-305
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., Blennow, K. (1999) Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol, 56(6): 673-80
Andreasen, N., Minthon, L., Clarberg, A., Davidsson, P., Gottfries, J., Vanmechelen, E., Vanderstichele, H., Winblad, B., Blennow, K. (1999) Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology, 53(7): 1488-94
Bateman, R.J., Wen, G., Morris, J.C., Holzman, D.M. (2007) Fluctuations of CSF amyloid-ss levels: Implications for a diagnostic and therapeutic biomarker. Neurology, 68(9): 666
Blennow, K. (2004) Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx, 1(2): 213-25
Blennow, K., Hampel, H. (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol, 2(10): 605-13
Dekosky, S.T., Marek, K. (2003) Looking backward to move forward: Early detection of neurodegenerative disorders. Science, 302(5646): 830-4
Dubois, B., Feldman, H., Jakova, C., DeKosky, S.T., Barberger-Gateau, P., Cuuuings, J., i dr. (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ARDA criteria. Lancet Neurology, 6(8): 734
Folstein, M.F., Folstein, S.E., McHugh, P.R. (1975) 'Mini-mental state': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12(3): 189-98
Galasko, D., Hansen, L.A., Katzman, R., Wiederholt, W., Masliah, E., Terry, R., Hill, L.R., Lessin, P., Thal, L.J. (1994) Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol, 51(9): 888-95
Geddes, J.W., Tekirian, T.L., Soultanian, N.S., Ashford, J.W., Davis, D.G., Markesbery, W.R. (1997) Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging, 18(4 Suppl): S99-105
Hampel, H., Buerger, K., Zinkowski, R., Teipel, S.J., Goernitz, A., Andreasen, N., Sjoegren, M., Debernardis, J., Kerkman, D., Ishiguro, K., Ohno, H., Vanmechelen, E., Vanderstichele, H., Mcculloch, C. (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry, 61(1): 95-102
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., Minthon, L. (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology, 5(3): 228
Herholz, K., Salmon, E., Perani, D., i dr. (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage, 17(1): 302-16
Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E., Blennow, K. (2001) Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett, 297(3): 187-90
Hesse, C., Rosengren, L., Vanmechelen, E., Vanderstichele, H., Jensen, C., Davidsson, P., Blennow, K. (2000) Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis, 2(3-4): 199-206
Jack, C.R., Dickson, D.W., Parisi, J.E., Xu, Y.C., Cha, R.H., O.P.C., Edland, S.D., Smith, G.E., Boeve, B.F., Tangalos, E.G., Kokmen, E., Petersen, R.C. (2002) Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology, 58(5): 750-7
Jensen, M., Schröder, J., Blomberg, M., Engvall, B., Pantel, J., Ida, N., Basun, H., Wahlund, L.O., Werle, E., Jauss, M., Beyreuther, K., Lannfelt, L., Hartmann, T. (1999) Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol, 45(4): 504-11
Kanemaru, K., Kameda, N., Yamanouchi, H. (2000) Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology, 54(9): 1875-6
Lansbury, P.T. (2004) Back to the future: The 'old-fashioned' way to new medications for neurodegeneration. Nat Med, 10 Suppl: S51-7
Lewzuck, P., Beck, G., Esselmann, H., Bruckmoser, R., Zimmermann, R., Fiszer, M., i dr. (2006) Effect of sample collection tubes on cerebrospinal fluid concentrations on tau proteins and amyloid beta peptides. Clin Chem, 52(2): 332−4
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M. (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology, 34(7): 939-44
Molina, L., Touchon, J., Herpé, M., Lefranc, D., Duplan, L., Cristol, J.P., Sabatier, R., Vermersch, P., Pau, B., Mourton, C. (1999) Tau and apo E in CSF: Potential aid for discriminating Alzheimer's disease from other dementias. Neuroreport, 10(17): 3491-5
Motter, R., Vigo, C., Kholodenko, D., Barbour, R., Johnson, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R. (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol, 38(4): 643-8
Otto, M., Wiltfang, J., Tumani, H., Zerr, I., Lantsch, M., Kornhuber, J., Weber, T., Kretzschmar, H.A., Poser, S. (1997) Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett, 225(3): 210-2
Price, J.C., Klunk, W.E., Lopresti, B.J., Lu, X., Hoge, J.A., Ziolko, S.K. (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. Journal of Cerebral Blood Flow & Metabolism, 25(11): 1528
Riemenschneider, M., Wagenpfeil, S., Vanderstichele, H., Otto, M., Wiltfang, J., Kretzschmar, H., Vanmechelen, E., Förstl, H., Kurz, A. (2003) Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry, 8(3): 343-7
Schoonenboom, N.S.M., Pijnenburg, Y.A.L., Mulder, C., Rosso, S.M., van Elk, E., van Kamp, G.J., van Swieten, J.C., Scheltens, P. (2004) Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology, 62(9): 1580-4
Schoonenboom, N.S.M., Mulder, C., Vanderstichele, H., van Elk, E., Kok, A., van Kamp, G.J., Scheltens, P., Blankenstein, M.A. (2005) Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: Implications for use in clinical practice. Clin Chem, 51(1): 189-95
Seab, J.P., Jagust, W.J., Wong, S.T., Roos, M.S., Reed, B.R., Budinger, T.F. (1988) Quantitative NMR measurements of hippocampal atrophy in Alzheimer's disease. Magn Reson Med, 8(2): 200-8
Silverman, D.H., Small, G.W., Chang, C.Y., Lu, C.S., de Kung, A.M.A., Chen, W., Czernin, J., i dr. (2001) Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA, 286(17): 2120-7
Sjögren, M., Davidsson, P., Tullberg, M., Minthon, L., Wallin, A., Wikkelso, C., Granérus, A.K., Vanderstichele, H., Vanmechelen, E., Blennow, K. (2001) Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry, 70(5): 624-30
Sjögren, M., Minthon, L., Davidsson, P., Granérus, A., Clarberg, A., Vanderstichele, H., Vanmechelen, E., Wallin, A., Blennow, K. (2000) CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm, 107(5): 563-79
Strozyk, D., Blennow, K., White, L.R., Launer, L.J. (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology, 60(4): 652-6
Tierney, M.C., Fisher, R.H., Lewis, A.J., Zorzitto, M.L., Snow, W.G., Reid, D.W., Nieuwstraten, P. (1988) The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: A clinicopathologic study of 57 cases. Neurology, 38(3): 359-64
van de Pol, L.A., Hensel, A., Barkhof, F., Gertz, H.J., Scheltens, P., van der Flier, W.M. (2006) Hippocampal atrophy in Alzheimer disease: Age matters. Neurology, 66(2): 236-8
Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., van de Voorde, A., Martin, J.J., Cras, P. (1993) Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem, 61(5): 1828-34
Vanmechelen, E., Vanderstichele, H., Davidsson, P., van Kerschaver, E., van der Perre, B., Sjögren, M., Andreasen, N., Blennow, K. (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett, 285(1): 49-52